{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:31:48Z","timestamp":1791498708562,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing National Science Foundation","award":["H2018206591"],"award-info":[{"award-number":["H2018206591"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"Abstract<\/jats:title>\n \n Purpose<\/jats:title>\n \n This study aims to investigate the clinical and molecular differences between diffuse large B-cell lymphoma (DLBCL) patients with MYD88\n L265P<\/jats:sup>\n and MYD88\n other<\/jats:sup>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n DLBCL patients with MYD88 variations were collected from the Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CHCAMS), and Suzhou Municipal Hospital from February 6th, 2007 to May 20th, 2022. Clinicopathological parameters and treatment outcomes between MYD88\n L265P<\/jats:sup>\n and MYD88\n other<\/jats:sup>\n were investigated.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 132 patients with MYD88 variations from a cohort of 475 DLBCL patients were included, among which, 78 were MYD88\n L265P<\/jats:sup>\n , while 54 were MYD88\n other<\/jats:sup>\n . MYD88\n L265P<\/jats:sup>\n was more common in non-GCB subtype than MYD88\n other<\/jats:sup>\n (83% vs. 60%,\n P<\/jats:italic>\n \u2009=\u20090.004). Besides, MYD88\n L265P<\/jats:sup>\n was significantly related to higher proportion of testicle\/ central nervous system involvement (31% vs. 6%,\n P<\/jats:italic>\n \u2009<\u20090.001), PIM1 mutation (71% vs. 39%,\n P<\/jats:italic>\n \u2009<\u20090.001), and PIM1 hypermutation (28% vs. 11%,\n P<\/jats:italic>\n \u2009=\u20090.018), compared with MYD88\n other<\/jats:sup>\n . Compared with MYD88\n L265P<\/jats:sup>\n , MYD88\n other<\/jats:sup>\n were more likely to have higher percentage of advanced stage (60% vs. 42%,\n P<\/jats:italic>\n \u2009=\u20090.044), extranodal site\u2009\u2265\u20092 (45% vs. 28%,\n P<\/jats:italic>\n \u2009=\u20090.044), elevated LDH (55% vs. 35%,\n P<\/jats:italic>\n \u2009=\u20090.033), positive CD10 expression (36% vs. 16%,\n P<\/jats:italic>\n \u2009=\u20090.009), BCL-6 translocation (20% vs. 8%,\n P<\/jats:italic>\n \u2009=\u20090.033), and NOTCH pathway gene alteration (24% vs. 13%,\n P<\/jats:italic>\n \u2009=\u20090.040). In non-GCB DLBCL subtype, patients with MYD88\n other<\/jats:sup>\n were significantly associated with worse progression free survival (PFS) than those with MYD88\n L265P<\/jats:sup>\n when treated initially with R-CHOP\/R-CHOP-like regimen (\n P<\/jats:italic>\n \u2009=\u20090.010).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n The findings of this study indicate that DLBCL patients with MYD88\n L265P<\/jats:sup>\n and MYD88\n other<\/jats:sup>\n are likely to be two subgroups with different clinical and molecular characteristics. The survival of patients with MYD88\n other<\/jats:sup>\n is not superior than those with MYD88\n L265P<\/jats:sup>\n , even poorer when focusing on the non-GCB subtype.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00432-023-04714-1","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T06:03:22Z","timestamp":1682316202000},"page":"8483-8494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"149","author":[{"given":"Yan","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zucheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"issue":"7","key":"4714_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"6769","key":"4714_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503\u2013511. https:\/\/doi.org\/10.1038\/35000501","journal-title":"Nature"},{"issue":"5","key":"4714_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24(5):679\u2013690. https:\/\/doi.org\/10.1038\/s41591-018-0016-8","journal-title":"Nat Med"},{"issue":"7247","key":"4714_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature07968","volume":"459","author":"M Compagno","year":"2009","unstructured":"Compagno M, Lim WK, Grunn A et al (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459(7247):717\u2013721. https:\/\/doi.org\/10.1038\/nature07968","journal-title":"Nature"},{"issue":"12","key":"4714_CR5","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","volume":"194","author":"RE Davis","year":"2001","unstructured":"Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194(12):1861\u20131874. https:\/\/doi.org\/10.1084\/jem.194.12.1861","journal-title":"J Exp Med"},{"issue":"7277","key":"4714_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G et al (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88\u201392. https:\/\/doi.org\/10.1038\/nature08638","journal-title":"Nature"},{"issue":"9","key":"4714_CR7","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-16-1922","volume":"23","author":"S Dubois","year":"2017","unstructured":"Dubois S, Viailly PJ, Bohers E et al (2017a) Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-Cell lymphoma: analysis of 361 cases. Clin Cancer Res 23(9):2232\u20132244. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1922","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4714_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3322\/caac.20087","volume":"60","author":"CR Flowers","year":"2010","unstructured":"Flowers CR, Sinha R, Vose JM (2010) Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 60(6):393\u2013408. https:\/\/doi.org\/10.3322\/caac.20087","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4714_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275\u2013282. https:\/\/doi.org\/10.1182\/blood-2003-05-1545","journal-title":"Blood"},{"issue":"8","key":"4714_CR10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2016-10-747303","volume":"130","author":"O Havranek","year":"2017","unstructured":"Havranek O, Xu J, Kohrer S et al (2017) Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood 130(8):995\u20131006. https:\/\/doi.org\/10.1182\/blood-2016-10-747303","journal-title":"Blood"},{"issue":"11","key":"4714_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.it.2006.09.002","volume":"27","author":"KJ Ishii","year":"2006","unstructured":"Ishii KJ, Akira S (2006) Innate immune recognition of, and regulation by. DNA. Trends Immunol. 27(11):525\u2013532. https:\/\/doi.org\/10.1016\/j.it.2006.09.002","journal-title":"DNA. Trends Immunol."},{"issue":"5963","key":"4714_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1126\/science.1183021","volume":"327","author":"A Iwasaki","year":"2010","unstructured":"Iwasaki A, Medzhitov R (2010) Regulation of adaptive immunity by the innate immune system. Science 327(5963):291\u2013295. https:\/\/doi.org\/10.1126\/science.1183021","journal-title":"Science"},{"issue":"9","key":"4714_CR13","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1002\/ijc.33049","volume":"147","author":"S Jiang","year":"2020","unstructured":"Jiang S, Qin Y, Jiang H et al (2020a) Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. Int J Cancer 147(9):2611\u20132620. https:\/\/doi.org\/10.1002\/ijc.33049","journal-title":"Int J Cancer"},{"issue":"2","key":"4714_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11523-020-00710-4","volume":"15","author":"S Jiang","year":"2020","unstructured":"Jiang S, Qin Y, Gui L et al (2020b) Genomic alterations and MYD88(MUT) variant mapping in patients with diffuse large B-cell lymphoma and response to ibrutinib. Target Oncol 15(2):221\u2013230. https:\/\/doi.org\/10.1007\/s11523-020-00710-4","journal-title":"Target Oncol"},{"issue":"28","key":"4714_CR15","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3452\u20133459. https:\/\/doi.org\/10.1200\/JCO.2011.41.0985","journal-title":"J Clin Oncol"},{"issue":"20","key":"4714_CR16","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA et al (2020) Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood 135(20):1759\u20131771. https:\/\/doi.org\/10.1182\/blood.2019003535","journal-title":"Blood"},{"issue":"7332","key":"4714_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332):115\u2013119. https:\/\/doi.org\/10.1038\/nature09671","journal-title":"Nature"},{"key":"4714_CR18","doi-asserted-by":"publisher","first-page":"11515","DOI":"10.2147\/CMAR.S269624","volume":"12","author":"Y Qin","year":"2020","unstructured":"Qin Y, Jiang S, Liu P et al (2020) Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients. Cancer Manag Res 12:11515\u201311522. https:\/\/doi.org\/10.2147\/CMAR.S269624","journal-title":"Cancer Manag Res"},{"key":"4714_CR19","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2021.0193","author":"Y Qin","year":"2021","unstructured":"Qin Y, Chen H, Liu P et al (2021) Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP. Cancer Biol Med. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2021.0193","journal-title":"Cancer Biol Med"},{"issue":"2","key":"4714_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS et al (2017) Genetic and functional drivers of diffuse large B cell lymphoma. Cell 171(2):481-494.e15. https:\/\/doi.org\/10.1016\/j.cell.2017.09.027","journal-title":"Cell"},{"issue":"11","key":"4714_CR21","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-15-1525","volume":"22","author":"J Rovira","year":"2016","unstructured":"Rovira J, Karube K, Valera A et al (2016a) MYD88 l265p mutations, but no other variants, identify a subpopulation of DLBCL patients of activated B-cell origin, extranodal involvement, and poor outcome. Clin Cancer Res 22(11):2755\u20132764. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1525","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4714_CR22","first-page":"83","volume":"102","author":"E Sabattini","year":"2010","unstructured":"Sabattini E, Bacci F, Sagramoso C, Pileri SA (2010) WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 102(3):83\u201387","journal-title":"Pathologica"},{"issue":"15","key":"4714_CR23","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW et al (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378(15):1396\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa1801445","journal-title":"N Engl J Med"},{"issue":"7","key":"4714_CR24","doi-asserted-by":"publisher","first-page":"e221","DOI":"10.1002\/ctm2.221","volume":"10","author":"R Shen","year":"2020","unstructured":"Shen R, Xu PP, Wang N et al (2020) Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma. Clin Transl Med 10(7):e221. https:\/\/doi.org\/10.1002\/ctm2.221","journal-title":"Clin Transl Med"},{"key":"4714_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpt.2022.09.006","author":"Y Shi","year":"2022","unstructured":"Shi Y, Chen H, Qin Y et al (2022) Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005\u20132018). Cancer Pathogen Ther. https:\/\/doi.org\/10.1016\/j.cpt.2022.09.006","journal-title":"Cancer Pathogen Ther"},{"issue":"4","key":"4714_CR26","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD et al (2020) a probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37(4):551\u201356814. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.015","journal-title":"Cancer Cell"},{"issue":"5","key":"4714_CR27","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/hon.3073","volume":"40","author":"J Xie","year":"2022","unstructured":"Xie J, Shen X, Shi Q et al (2022) Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma. Hematol Oncol 40(5):885\u2013893. https:\/\/doi.org\/10.1002\/hon.3073","journal-title":"Hematol Oncol"},{"key":"4714_CR28","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3389\/fphar.2018.01497","volume":"9","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Wang H, Ren C et al (2018) Correlation between C-MYC, BCL-2, and BCL-6 protein expression and gene translocation as biomarkers in diagnosis and prognosis of diffuse large B-cell lymphoma. Front Pharmacol 9:1497. https:\/\/doi.org\/10.3389\/fphar.2018.01497","journal-title":"Front Pharmacol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04714-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04714-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04714-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T16:40:53Z","timestamp":1690476053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04714-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4714"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04714-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2547016\/v1","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}